ATE418969T1 - Carvedilol enthaltende pharmazeutische zusammensetzung mit kontrollierter freisetzung - Google Patents

Carvedilol enthaltende pharmazeutische zusammensetzung mit kontrollierter freisetzung

Info

Publication number
ATE418969T1
ATE418969T1 AT06779688T AT06779688T ATE418969T1 AT E418969 T1 ATE418969 T1 AT E418969T1 AT 06779688 T AT06779688 T AT 06779688T AT 06779688 T AT06779688 T AT 06779688T AT E418969 T1 ATE418969 T1 AT E418969T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
controlled release
release pharmaceutical
composition containing
containing carvedilol
Prior art date
Application number
AT06779688T
Other languages
English (en)
Inventor
Pal Fekete
Zoltan Budavari
Zsolt Zsigmond
Agnes Bozso
Huszar Magdolna Leventiszne
Zoltanne Palfi
Palne Szentgroti
Karacs Erika Davidne
Kuncze Aniko Turoczine
Krisztina Abraham
Original Assignee
Egis Gyogyszergyar Nyilvanosan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyogyszergyar Nyilvanosan filed Critical Egis Gyogyszergyar Nyilvanosan
Application granted granted Critical
Publication of ATE418969T1 publication Critical patent/ATE418969T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06779688T 2005-08-26 2006-08-23 Carvedilol enthaltende pharmazeutische zusammensetzung mit kontrollierter freisetzung ATE418969T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0500803A HU227490B1 (en) 2005-08-26 2005-08-26 Sustained release pharmaceutical preparation containing carvedilol

Publications (1)

Publication Number Publication Date
ATE418969T1 true ATE418969T1 (de) 2009-01-15

Family

ID=89986232

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06779688T ATE418969T1 (de) 2005-08-26 2006-08-23 Carvedilol enthaltende pharmazeutische zusammensetzung mit kontrollierter freisetzung

Country Status (11)

Country Link
EP (1) EP1928431B8 (de)
AT (1) ATE418969T1 (de)
DE (1) DE602006004610D1 (de)
DK (1) DK1928431T3 (de)
EA (1) EA013058B1 (de)
ES (1) ES2321980T3 (de)
HU (1) HU227490B1 (de)
NO (1) NO20081481L (de)
PL (1) PL1928431T3 (de)
PT (1) PT1928431E (de)
WO (1) WO2007023325A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP2387994A1 (de) * 2006-01-27 2011-11-23 Eurand, Inc. Arzneimittelabgabesysteme mit einem schwachen Basisarzneimittel und organischen Säuren
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
EP2056797A2 (de) 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH System mit kontrollierter freisetzung und verfahren zu seiner herstellung
HU227881B1 (en) * 2007-02-23 2012-05-29 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
MX2010003032A (es) 2007-09-21 2010-04-09 Evonik R Hm Gmbh Composicion farmaceutica opioide de liberacion controlada ph dependiente con resistencia contra la influencia del etanol.
WO2009047800A2 (en) * 2007-10-09 2009-04-16 Lupin Limited Oral controlled release composition of carvedilol
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
CN103099793B (zh) * 2013-02-06 2015-07-15 中国人民解放军第二军医大学 片剂及其制备方法
JP7336187B2 (ja) * 2017-11-30 2023-08-31 日本ケミファ株式会社 多層構造を有する粒子状医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2426811A1 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
AU2003288608A1 (en) * 2002-12-20 2004-07-14 Ranbaxy Laboratories Limited Controlled release, multiple unit drug delivery systems

Also Published As

Publication number Publication date
HUP0500803A3 (en) 2008-03-28
DK1928431T3 (da) 2009-04-20
PL1928431T3 (pl) 2009-07-31
EP1928431A2 (de) 2008-06-11
EA013058B1 (ru) 2010-02-26
EP1928431B8 (de) 2009-04-08
HUP0500803A2 (en) 2007-05-29
HU227490B1 (en) 2011-07-28
DE602006004610D1 (de) 2009-02-12
WO2007023325A2 (en) 2007-03-01
EP1928431B1 (de) 2008-12-31
EA200800666A1 (ru) 2008-06-30
HU0500803D0 (en) 2005-11-28
ES2321980T3 (es) 2009-06-15
NO20081481L (no) 2008-05-19
WO2007023325A3 (en) 2007-06-28
PT1928431E (pt) 2009-03-25

Similar Documents

Publication Publication Date Title
NO20081481L (no) Farmasoytisk sammensetning inneholdende carvedilol, med regulert frigivning
WO2009059701A3 (de) Retardtabletten mit hydromorphon
IL181117A0 (en) Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition
WO2009036253A3 (en) Medical devices having bioerodable layers for the release of therapeutic agents
WO2009113703A3 (en) Orally-disintegrating solid preparation
TR201902233T4 (tr) Hızlı çözünen katı dozaj formu.
DE502005009109D1 (de) Feste, oral applizierbare pharmazeutische darreichungsformen enthaltend rivaroxaban mit modifizierter freisetzung
WO2009009628A3 (en) Endoprosthesis coating
WO2011060256A3 (en) Bilayer tablet formulations
WO2010053337A3 (ko) 서방성 미립자 및 이의 제조방법
WO2007149801A3 (en) Enteric coated particles containing an active ingredient
WO2009058950A3 (en) Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
WO2010053306A3 (ko) 메칠페니데이트의 방출 제어용 약제학적 조성물
FI20085543L (fi) Irrokemateriaalikoostumus, pohjamateriaali ja menetelmä pohjamateriaalin valmistamiseksi, pintakäsittelyaine pohjamateriaalia varten sekä pintakäsittelyaineen käyttö
CL2012002909A1 (es) Procedimiento de preparación de una composición farmacéutica que comprenden a) un centro granulado constituido por granos de principio activo aglomerados en presencia de aglomerante y b) una capa de recubrimiento de dicho centro granulado constituido por matriz grasa; composición farmacéutica; y su uso para administración oral
MX339587B (es) Pelicula que se puede rotular con laser resistente al calor.
WO2011101866A3 (en) Gastric retention formulation containing baclofen
WO2007041367A3 (en) Oral composition containing a salivation inducing agent
WO2012091408A3 (en) Matrix type antimicrobial vehicle and manufacturing method thereof
JP2010502437A5 (de)
MX280211B (es) Polimero, un metodo para producir el polimero y una mezcla de cemento que utiliza el mismo.
WO2007113207A3 (en) Coated formulations
WO2008047361A3 (en) A coating or cladding and method of preparing same
WO2010079052A3 (en) Nanoparticle compositions
EP1997485A4 (de) Pharmazeutische zusammensetzung mit meglitinid zur prävention von leberfibrose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1928431

Country of ref document: EP